• SPX
  • $5,712.69
  • -0.28 %
  • -$16.11
  • DJI
  • $41,794.60
  • -0.61 %
  • -$257.59
  • N225
  • $38,474.90
  • 1.11 %
  • $421.23
  • FTSE
  • $8,204.56
  • 0.25 %
  • $20.32
  • IXIC
  • $18,179.98
  • -0.33 %
  • -$59.93
Legend Biotech Corporation (LEGN) Stock Price, News & Analysis

Legend Biotech Corporation (LEGN) Stock Price, News & Analysis

Currency in USD Disclaimer

$43.62

-$0.74

(-1.67%)

Day's range
$42.86
Day's range
$44.78
50-day range
$42
Day's range
$59.62
  • Country: US
  • ISIN: US52490G1022
52 wk range
$38.6
Day's range
$70.13


We are preparing, please wait

Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score 6.85
  • Piotroski Score 4.00
  • Grade Buy
  • Symbol (LEGN)
  • Company Legend Biotech Corporation
  • Price $43.62
  • Changes Percentage (-1.67%)
  • Change -$0.74
  • Day Low $42.86
  • Day High $44.78
  • Year High $70.13

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery and development of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM), as well as a comparison of the treatment with standard triplet therapy in revlimid-refractory multiple myeloma. The company also has a portfolio of earlier-stage autologous product candidates, which are in Phase I clinical trials for the treatment of gastric cancer and T cell lymphoma. In addition, it is developing CAR-T product candidates targeting CD20/CD22/CD19 for the treatment of non-hodgkins lymphoma, diffuse large B-cell lymphoma, and acute lymphoblastic leukemia. Further, the company has product candidates in early preclinical and clinical development for the treatment of solid tumors as well as infectious diseases. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. Legend Biotech Corporation was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.

  • Last Earnings
  • Ex-Dividend for 5/16 Dividend
  • Dividend Payable
  • Today N/A
  • Next Earnings (Estimated) 11/11/2024
  • Fiscal Year End N/A

  • Average Stock Price Target $86.00
  • High Stock Price Target $94.00
  • Low Stock Price Target $60.00
  • Potential Upside/Downside N/A
  • Consensus Rating Strong Sell
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) -$2.58
  • Trailing P/E Ratio -17.66
  • Forward P/E Ratio -17.66
  • P/E Growth -17.66
  • Net Income $-518,254,000

Income Statement

Quarterly

Annual

Latest News of LEGN

The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.

Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.


We are preparing, please wait

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In


or

download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to Stocks.News!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.